The structural profiles are close, with Elisa Oyj carrying a narrow edge on growth. West Pharmaceutical Services still has the edge on growth, which keeps the comparison from looking entirely one-sided. In the market, West Pharmaceutical Services carries the stronger setup — intact trend against Elisa Oyj's broken trend. That leaves a split case: the structural lead stays with Elisa Oyj, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ELISA.HE: STOXX 600, WST: S&P 500).
Growth points more clearly toward West Pharmaceutical Services, Inc., even if the broader score still leans toward Elisa Oyj.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.
Most of the shared profile comes through revenue growth trajectory and capital structure.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
West Pharmaceutical Services, Inc. occupies the cheaper side of the setup map, although Elisa Oyj still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ELISA.HE and WST each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The main growth separation is very wide, driven by a meaningfully stronger expansion profile.
On the market side, West Pharmaceutical Services carries the stronger trend while Elisa Oyj's trend has broken — the market setup does not confirm the structural advantage.
Growth is the clearest driver of the lead, with valuation adding further support — though growth still provides a real counterweight.
Break down the ELISA.HE vs WST comparison across all dimensions with the full interactive tool.
Explore how ELISA.HE and WST each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.